Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers

Antibody Therapeutics
N MohanWen Jin Wu

Abstract

Trastuzumab, an epidermal growth factor receptor 2 (HER2) targeting humanized monoclonal antibody, has been approved for the treatment HER2-positive breast cancer and HER2-positve metastatic gastric cancer. However, cardiotoxicity associated with its clinical application poses challenges for clinicians and patients, mechanisms of which are still evolving. This review will summarize the current mechanistic understanding of trastuzumab-mediated cardiotoxicity, discuss the novel role of DNA topoisomerase IIB as a shared target for enhanced cardiotoxicity induced by trastuzumab and anthracyclines-based combination regimens, and speculate the potential impact of trastuzumab intervention in immune checkpoint inhibitors-based therapies.

References

Aug 28, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Baselga
May 2, 2002·Nature Medicine·Steven A CroneKuo-Fee Lee
Jan 30, 2004·Recent Progress in Hormone Research·Alejandra NegroKuo-Fen Lee
Jul 6, 2007·The New England Journal of Medicine·Clifford A Hudis
Aug 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Melinda L TelliAlice E Guardino
Dec 17, 2008·Breast Cancer Research and Treatment·Deepa WadhwaDavinder S Jassal
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil L Spector, Kimberly L Blackwell
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Sep 6, 2012·Journal of the National Cancer Institute·Erin J Aiello BowlesUNKNOWN Pharmacovigilance Study Team
Oct 30, 2012·Nature Medicine·Sui ZhangEdward T H Yeh
Aug 30, 2014·Journal of the American College of Cardiology·Pimprapa Vejpongsa, Edward T H Yeh
May 13, 2015·Nature Reviews. Cardiology·Michael S Ewer, Steven M Ewer
Sep 30, 2015·Nature Reviews. Cardiology·Nishant Mohan, Wen Jin Wu
Feb 3, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chau T DangClifford A Hudis
Oct 8, 2016·British Journal of Pharmacology·Balazs T NemethPal Pacher
Nov 3, 2016·The New England Journal of Medicine·Douglas B JohnsonJavid J Moslehi
Feb 24, 2017·Breast Care·Andreas D HartkopfSara Y Brucker
Jun 3, 2017·Expert Opinion on Drug Metabolism & Toxicology·Milos DokmanovicWen Jin Wu
Jun 14, 2017·Cancer Cell·Gabriel Abril-Rodriguez, Antoni Ribas
Nov 7, 2017·ESMO Open·Gilda VarricchiCarlo Gabriele Tocchetti

❮ Previous
Next ❯

Citations

Feb 23, 2020·Journal of Cardiovascular Translational Research·Emily A PinheiroPaul W Burridge
Apr 29, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Doaa Abd AlghafarNiamh E Buckley
May 16, 2020·Journal of Cellular and Molecular Medicine·Rao Fu, Jing-Shan Tong
Nov 21, 2019·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Alberto Aimo, Alessia Gimelli
Oct 28, 2020·CA: a Cancer Journal for Clinicians·Nicole L StoutJulie K Silver
Jan 24, 2021·Journal of Biomedical Science·Tomasz Klaus, Sameer Deshmukh
Jan 14, 2021·International Journal of Molecular Sciences·Giandomenico BisacciaBarbara Ghinassi
Mar 27, 2021·World Journal of Clinical Oncology·Asim KichlooManidhar Lekkala
Apr 7, 2021·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Neeraj Chhabra, Joseph Kennedy
Apr 30, 2021·Frontiers in Cell and Developmental Biology·Shanshan WeiWenqun Li
Jun 27, 2021·Molecular Cancer Therapeutics·Zhijian Duan, Mitchell Ho

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Related Papers

The Journal of the British Menopause Society
Simon ChowdhuryPaul Ellis
European Journal of Heart Failure
Patrick J PerikDirk J van Veldhuisen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Yoriko Yamashita-KashimaKaori Fujimoto-Ouchi
© 2022 Meta ULC. All rights reserved